Special Issue "Phenotypic Screening"
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 13167
Interests: medicinal chemistry; drug discovery; phenotypic screening; biotransformation; drug metabolism; diabetes; Duchenne muscular dystrophy
2. Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3PQ, UK
Interests: medicinal chemistry; drug discovery; phenotypic screening; target identification; regenerative medicine; neuromuscular disease; cancer; inflammation
Phenotypic screening and more broadly phenotypic drug discovery (PDD) rely on methods where the molecular mechanism is not known or assumed and uses empirical lead generation to deliver novel drug candidates in the clinic. Though target-based approaches, supported by the rapid progress in genetics and molecular biology, have dominated drug discovery in the past 30 years, there is recently a resurgence of PDD. The relative simplicity of target-based approaches facilitated testing of increasing numbers of compounds, initially thought of as increasing diversity and furthering the odds of successful drug discovery. However, a disconnect between in vitro and in vivo systems was often observed, as a result of stirring away from physiologically relevant conditions that cease to accurately simulate disease. PDD, on the other hand, is more costly and slow in the early stages, requiring rigorous validation and/or target identification, but with a better understanding of the risks and challenges, it can be a powerful tool leading to increased probabilty of success for drug candidates, but also to the identification of novel drug targets that can be used alone or in combination with existing therapeutics.
The present Special Issue is aimed at covering improvements in library design, screening, assay cascade, and chemoinformatics tools that expedite modern PDD, presenting successful medicinal chemistry efforts in PDD, and further target identification campaigns that originated from PDD. We look forward to receiving these and other relevant contributions.
Dr. Maria Chatzopoulou
Prof. Dr. Angela Russell
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2300 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- phenotypic screening
- drug discovery
- high-throughput screening
- high-content screening
- hit triage
- lead identification
- lead optimisation
- assay cascade
- apparent activity
- assay interference
- structure–activity relationships
- library design
- target identification/validation